We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
SEC Associates won a spot on the contract team working with the HHS, RTI International and the National Governors Association (NGA) to examine privacy and security laws and business practices that affect the ability of states to exchange interoperable ehealth information, the company announced.
Most prescription drug plans operating under the new Medicare Rx benefit cover 80 or more of the 100 most often prescribed drugs for seniors, said the head of the Centers for Medicare & Medicaid Services (CMS).
The Medicare prescription drug benefit has filled nearly 10 million prescriptions in the first 10 days of its existence, but the chief of the Centers for Medicare & Medicaid Services (CMS) acknowledged that some beneficiaries are still having trouble obtaining needed medications.
Most prescription drug plans operating under the new Medicare Rx benefit cover 80 or more of the 100 most often prescribed drugs for seniors, said the head of the Centers for Medicare & Medicaid Services (CMS).
The Medicare prescription drug benefit has filled nearly 10 million prescriptions in the first 10 days of its existence, but the chief of the Centers for Medicare & Medicaid Sevices (CMS) acknowledged that some beneficiaries are having trouble obtaining needed medications.
The Centers for Medicare and Medicaid Services (CMS) has revised its 2006 physician fee schedule to allow reimbursement for use of medical laser devices in an office setting.
The Centers for Medicare & Medicaid Services (CMS) recently issued a report observers say is the first development in what will likely be a contentious battle over drug costs, both on Capitol Hill and in state legislatures this year.
The Centers for Medicare & Medicaid Services (CMS) recently issued a report observers say is the first development in what will likely be a contentious battle over drug costs, both on Capitol Hill and in state legislatures this year.
The Generic Pharmaceutical Association (GPhA) recently took the Congressional Budget Office (CBO) to task for its recent letter to Sen. Charles Schumer (D-N.Y.), in which CBO downplayed potential consequences of raising the drug rebates paid by generic drug manufacturers to the Medicaid program.
Pharmaceutical companies are doing a better job making clinical trial data public, but some of the industry’s largest players are continuing to hide key information, according to a new study.